SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.61+0.4%10:41 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: zeta19615/15/2005 11:17:58 PM
   of 52153
 
Message 21326992

Former_pgs..Note my bold..Tarceva was not tested in P2 trials to assess a signal..hence, my opinion remains as stated yesterday..marketing muscle when unchecked or when co-sponsored by the very people who are supposed to care for onc patients, is unethical and creates stagnation...there is a reason why over 20 Billion dollars and countless fund raising hours spent since Nixon declared the war on cancer that we are where we are or not where we could be..that was the point of my post regarding the pancreatic OSIP/DNA trial..we need to look at the allocation of funds in order to make meaningful progress..otherwise the work of the NIH/NCI becomes/is? like the proverbial 'state job'..do the daily grind, grant proposals around what you think you'll get funded versus what deserves to get funded based on scientific merit and not on perks and payoffs..

And I place the responsibility squarely on my former collegues and treating physicians..

Zeta
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News